Slide 1: BioSyent Inc. Q3/YTD 2024 Results
BioSyent BioSyentInc. Inc. Q4 / FY 2023 Q3/YTD 2024Results Results MARCH 13,20, 2024 NOVEMBER 2024 PRESENTED BY: RENÉ GOEHRUM PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: 3 | www.biosyent.com | TSXV: RX | www.biosyent.com | TSXV: RX
3 | www.biosyent.com | TSXV: RX 3 | www.biosyent.com | TSXV: RX
Slide 4: Q3/YTD 2024 Sales Summary ($)
Q3/YTD 2024 Sales Summary ($) Q3 ’24 Q3 ‘24 vs. YTD ’24 YTD ‘24 vs. Sales ($) Q3 ’23 (%) Sales ($) YTD ’23 (%) Canadian Pharma ($) $8,303k +12% $24,385k +13% Cathejell® +4% +3% Combogesic® +37% +76% FeraMAX® Pd +10% +11% Gelclair® n/a n/a Inofolic® +186% n/a RepaGyn® +7% +13% Tibella® +26% +32% Inte
Slide 5: Sales, EBITDA and NIAT: Quarter ended September 30th
Sales, EBITDA and NIAT Quarter ended September 30th (Q3) +8% Record Quarterly Sales 10,000 +12% Canadian Pharma +31% 9,000 (40%) International Pharma +35% +47% Legacy 8,000 7,000 EBITDA / NIAT • EBITDA Margin 6,000 Q3 2024: 30% to Sales Q3 2023: 33% to Sales CAD (000's) 5,000 4,000 • NIAT Margin +49
Slide 6: Sales, EBITDA and NIAT: Year-to-Date ended September 30th
Sales, EBITDA and NIAT Year-to-Date ended September 30th (YTD) 30,000 Sales +13% +13% Canadian Pharma (24%) International Pharma 25,000 +14% +35% +45% Legacy EBITDA / NIAT 20,000 • EBITDA Margin YTD 2024: 27% to Sales CAD (000's) 15,000 YTD 2023: 27% to Sales • NIAT Margin 10,000 YTD 2024: 22% to Sa
Slide 7: Fully Diluted Earnings per Share
Fully Diluted Earnings per Share Quarter NIAT Diluted EPS 57 Consecutive Profitable Quarters Q3 2024 $2,307,894 $0.20 to Q3 2024 Q2 2024 $1,580,289 $0.13 $0.60 TTM Q1 2024 $1,768,727 $0.15 Q4 2023 $1,450,791 $0.12 Q3 2023 $2,350,900 $0.20 Q2 2023 $1,483,190 $0.12 $0.51 TTM Q1 2023 $1,175,246 $0.10 Q
Slide 8: 2024 YTD Highlights
2024 YTD Highlights Feb 2024: BioSyent named to 2024 TSX Venture 50 Mar/Jun/Sep 2024: Quarterly dividends of $0.045 paid (+12.5% increase) Apr 2024: FeraMAX® named #1 recommended iron supplement in Canada for ninth consecutive year Apr 2024: Extension of RepaGyn® and Proktis-M® Agreement to
Slide 9: 2024 YTD Highlights (Continued)
2024 YTD Highlights (Continued) Jun 2024: In-licensing of new endocrinology product for Canada Sept 2024: Acquisition of Tibelia® / Tibella ® (tibolone) global assets Jan – Sept 2024: 162,300 shares repurchased and cancelled under NCIB Nov 2024: Declaration of Q4 2024 dividend of $0.045/shar
Slide 10: Tibelia / Tibella (tibolone) Asset Purchase
Asset Purchase – September 2024 Tibelia® / Tibella® (tibolone) Acquired global rights, key contracts and IP related to tibolone: HRT drug for treatment of vasomotor symptoms of menopause Tibolone available for over 30 years worldwide Marketed in Canada by BioSyent Pharma under the Tibella® bra
Slide 11: Tibelia / Tibella (tibolone) Asset Purchase
Asset Purchase – September 2024 Tibelia® / Tibella® (tibolone) Acquired assets enable BioSyent to: Supply tibolone to existing distributors worldwide = incremental revenues starting early 2025 Expand distribution of tibolone to new markets worldwide = revenue growth potential Produce tibolon
Slide 12: Most recommended iron supplement in Canada
9 Most recommended iron supplement in Canada - pharmacists and physicians - 9 consecutive years(1) Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2024 Survey on OTC Counselling and Recom
Slide 13: FeraMAX LifeCycle Strategy
FeraMAX® LifeCycle Strategy Expanding leadership of FeraMAX® brand in Canada: “Iron health for life” FeraMAX® Pd platform introduced in October 2020 Patented delivery system based on Polydextrose Iron Complex (PDIC) FeraMAX® Pd Therapeutic 150 launched Nov 2020 FeraMAX® Pd Powder 15 launch
Slide 14: Growth Drivers
Growth Drivers New endocrinology asset FeraMAX® Pd Platform – Life Cycle Strategy In development Tibela® / Tibella® (tibolone) - HRT agent for menopause therapy Management of symptoms of PCOS Oncology supportive care product for Oral Mucositis Acquisition and in-licensing – ongoing 14 | www.biosyent
Slide 15: Cash Balance & Return on Equity
Cash Balance & Return on Equity (“RoE”) 30,000 25% • Zero Debt 29,290 27,785 27,562 20% 25,000 • TTM Sept 30’24 Cash from 19% 18% 20% Operations of $6.7 M 20,000 15% • TTM Sept 30’24 NCIB share buybacks: $2.2 M 15,000 • 249,700 shares CAD (000's) RoE % 10% 10,000 • TTM Sept 30’24 Net Dividends of $2
Slide 16: Innovations, Product Launches and Acquisitions
Innovations, Product Launches and Acquisitions Tibella® Jul 2020 FeraMAX® Pd Oct 2020 FeraMAX® Pd Therapeutic 150 Nov 2020 Combogesic® Dec 2020 FeraMAX® Pd Powder 15 Oct 2021 FeraMAX® Pd Maintenance 45 Mar 2023 Inofolic® Aug 2023 Gelclair® Nov 2023 Tibelia® Global Sep 2024 16 | www.biosyent.com | TS
Slide 17: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue growth & portfolio diversification. • 8 new product launches in Canada since July 2020 • Tibelia® / Tibella® (tibolone) Global Acquisition in Sept 2024 Cash: Dividends $27.6M Growth & Diversification Debt: Share $0M Bu
Slide 18: Stock Information
Stock Information As at November 15, 2024 Exchange & Trading Symbol 0% TSXV: RX November 15, 2024 Closing Stock Price (CAD) (TSXV): $11.06 52 Week Hi/Low (TSXV): $11.49 / $7.91 Issued Common Shares: 11,797,395 Treasury – RSU Shares in Trust (203,294) RSUs funded Outstanding Common Shares: 11,594,101
Slide 19: Profitable. Well Capitalized. Growth Assets.
PROFITABLE. WELL CAPITALIZED. GROWTH ASSETS. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 19 www.biosyent.com | TSXV: RX